Bienville Capital Management’s GSK GSK Stock Holding History

Bienville Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,825	Closed	-$244K	–	134
2019 Q2	$244K	Buy	4,825 +42	+0.9%	+$2.11K	0.03%	166
2019 Q1	$253K	Sell	4,783 -28	-0.6%	-$1.4K	0.03%	145
2018 Q4	$233K	Buy	4,811 +538	+13%	+$26.5K	0.05%	140
2018 Q3	$217K	Sell	4,273 -4	-0.1%	-$203	0.02%	102
2018 Q2	$218K	Buy	4,277 +207	+5%	+$10.4K	0.02%	115
2018 Q1	$204K	Sell	4,070 -2,726	-40%	-$127K	0.03%	123
2017 Q4	$306K	Sell	6,796 -375	-5%	-$17.3K	0.05%	139
2017 Q3	$368K	Buy	7,171 +74	+1%	+$3.75K	0.06%	102
2017 Q2	$387K	Buy	7,097 +257	+4%	+$13.7K	0.11%	94
2017 Q1	$365K	Sell	6,840 -14	-0.2%	-$710	0.09%	93
2016 Q4	$334K	Sell	6,854 -320	-4%	-$15.8K	0.07%	92
2016 Q3	$391K	Sell	7,174 -298	-4%	-$16.3K	0.1%	81
2016 Q2	$409K	Buy	7,472 +1,738	+30%	+$91.6K	0.11%	64
2016 Q1	$300K	Hold	5,734	–	–	0.1%	51
2015 Q4	$293K	Hold	5,734	–	–	0.1%	49
2015 Q3	$280K	Hold	5,734	–	–	0.12%	55
2015 Q2	$299K	Hold	5,734	–	–	0.12%	57
2015 Q1	$331K	Hold	5,734	–	–	0.19%	33
2014 Q4	$306K	Buy	+5,734	New	+$321K	0.25%	60

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bienville Capital Management's GSK Position: Q3 2019 in Review

Bienville Capital Management sold out of GSK (GSK) in Q3 2019, closing a stake of 4,825 shares — an estimated $244K sold.

Bienville Capital Management first reported a position in GSK in Q4 2014 and held it in 19 quarters. The position peaked at $409K in Q2 2016. 805 funds tracked by Wall St. Rank hold GSK as of Q3 2019.

Bienville Capital Management reported no remaining GSK position as of Q3 2019 after selling out during the quarter.
Bienville Capital Management sold 4,825 GSK shares in Q3 2019, an estimated $244K.
Bienville Capital Management first reported a position in GSK in Q4 2014 and held it in 19 quarters.
Bienville Capital Management's GSK position peaked at $409K in Q2 2016.
805 funds tracked by Wall St. Rank held GSK as of Q3 2019.

Based on Bienville Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.